Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) [Phase 2]

View source ↗

Summary

Acumen Pharmaceuticals is conducting a Phase 2 trial of intravenous Sabirnetug for early Alzheimer's disease (ALTITUDE-AD), and the study is currently active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Sabirnetug (sabirnetug)

Snippet

Sponsor: Acumen Pharmaceuticals | Conditions: Alzheimer Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING